FDA approvals for pediatric cancer indications using children's oncology group associated trials data

Area of Science:

• Pediatric Oncology
• Clinical Trial Networks
• Drug Regulatory Science

Background:

• The Children's Oncology Group (COG) is a major international network established in 2000, conducting over 330 clinical trials for pediatric, adolescent, and young adult cancers.
• An assessment was conducted on the role of COG trial data in Food and Drug Administration (FDA) approvals for pediatric oncology indications since 2000.

Purpose of the Study:

• To evaluate the contribution of Children's Oncology Group (COG) clinical trial data to Food and Drug Administration (FDA) approvals for pediatric oncology indications.
• To assess the impact of COG's data on regulatory success for pediatric cancer therapeutics.

Main Methods:

• A comprehensive review of all FDA approvals for pediatric oncology indications between January 1, 2000, and December 31, 2024.
• Data acquisition from the FDA website, ClinicalTrials.gov, and the COG database.

Main Results:

• Out of 53 FDA pediatric indication approvals for 37 drugs/biologics, 25 (47%) utilized COG trial data.
• Fifteen COG trials, supported by the National Cancer Institute (NCI) cooperative agreement award, contributed data for 14 indications (26% of all pediatric approvals).
• COG studies employed three distinct partnership models to support these approvals.

Conclusions:

• Approximately 50% of FDA-approved pediatric oncology indications were supported by COG trial data.
• The findings underscore the effectiveness of the COG's public-private partnership model in generating robust clinical evidence for regulatory approval.
• COG's contribution is critical for advancing pediatric cancer treatment and achieving regulatory success.